Get the Stockscreener App
373.91
0.29%
-1.59
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $373.91, with a volume of 1.36M.
It is down -0.29% in the last 24 hours and up +13.12% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$375.50
Open:
$372.01
24h Volume:
1.36M
Relative Volume:
0.48
Market Cap:
$201.40B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
26.27
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
+1.42%
1M Performance:
+13.12%
6M Performance:
+26.30%
1Y Performance:
+25.68%
1-Day Range:
$371.39
$377.00
1-Week Range:
$369.00
$380.58
52-Week Range:
$261.43
$385.12
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
373.61 | 202.42B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
1,014.12 | 965.26B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.40 | 595.03B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
225.28 | 396.51B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.87 | 323.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.31 | 312.78B | 54.72B | 14.02B | 15.32B | 7.1855 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Barclays Begins Coverage on Amgen (NASDAQ:AMGN) - MarketBeat
Barclays Initiates Coverage on Amgen (AMGN) with Equal-Weight Ra - GuruFocus
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
ICICI Prudential Asset Management Co Ltd Purchases 8,529 Shares of Amgen Inc. $AMGN - MarketBeat
Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More - 24/7 Wall St.
Barclays initiates Amgen stock coverage with Equalweight rating - Investing.com
Amgen Inc. $AMGN Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Announces Successful Issuance of $4 Billion in Senior Notes - GuruFocus
Amgen Prices $4 Billion Senior Unsecured Notes Offering - TipRanks
Amgen raises $4bn across four tranches as Amazon lurks - GlobalCapital
Amgen (NASDAQ: AMGN) sells four new series of senior notes - Stock Titan
Here's What the Street is Saying About Amgen Inc. (AMGN) - Finviz
Here’s what the street is saying about Amgen Inc. (AMGN) - MSN
Here’s What the Street is Saying About Amgen Inc. (AMGN) - Insider Monkey
P/E Ratio Insights for Amgen - Benzinga
Amgen (AMGN) Gets Target Price Increase by Wells Fargo | AMGN St - GuruFocus
Pharma Giants Amgen & Abbott Labs Commit to Transition Away from Horseshoe Crab Blood in Biomedical Testing Following Shareholder Engagement - As You Sow
NewEdge Wealth LLC Raises Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Axxcess Wealth Management LLC Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
Hodges Capital Management Inc. Sells 6,887 Shares of Amgen Inc. $AMGN - MarketBeat
Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed - Law360
Here’s what Argus Research and Guggenheim are saying about Amgen Inc. (AMGN) - MSN
Amgen Details Oncology R&D Push, IMDELLTRA Expansion and LUMAKRAS Updates at Citi Summit - Yahoo Finance
Amgen at Citi’s 2026 Virtual Oncology Summit: Expanding Cancer Therapies - Investing.com
AMGN: Transformative oncology pipeline advances with T cell engagers, AI, and precision therapies - TradingView
Wells Fargo Adjusts Amgen Price Target to $375 From $325, Maintains Equal Weight Rating - marketscreener.com
Rothschild & Co Redburn Boosts Amgen (NASDAQ:AMGN) Price Target to $200.00 - MarketBeat
Piper Sandler raises Amgen stock price target on drug pipeline - Investing.com
Amgen Stock Is Up 14% This Year on Dual Drug Approvals. Can the Rally Hold? - TIKR.com
First National Bank of Omaha Purchases Shares of 40,836 Amgen Inc. $AMGN - MarketBeat
Crestwood Advisors Group LLC Boosts Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc Files For Four-Part Senior Notes Offering Of Up To $4 Bln - TradingView
Amgen’s Uplizna now approved in EU to treat most adults with gMG - Myasthenia Gravis News
NEOS Investment Management LLC Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Skandinaviska Enskilda Banken AB publ Lowers Stake in Amgen Inc. $AMGN - MarketBeat
Zions Bancorporation National Association UT Sells 10,088 Shares of Amgen Inc. $AMGN - MarketBeat
Vanguard Group Inc. Purchases 165,281 Shares of Amgen Inc. $AMGN - MarketBeat
Public Sector Pension Investment Board Has $13.34 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Holdings Lowered by Fifth Third Bancorp - MarketBeat
Amgen Inc. (AMGN) Stock Analysis: Evaluating the Performance and Growth Potential of a Biotech Giant - DirectorsTalk Interviews
Amgen Inc (AMGN) Stock Price, Trades & News - GuruFocus
Why Amgen Inc. stock is seen as undervaluedWeekly Profit Analysis & Safe Capital Growth Tips - mfd.ru
Shell Asset Management Co. Has $2.82 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by State of New Jersey Common Pension Fund D - MarketBeat
A Look At Amgen (AMGN) Valuation After Strong Q4 Results And New UPLIZNA Approval - simplywall.st
PNC Financial Services Group Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
HighTower Advisors LLC Grows Position in Amgen Inc. $AMGN - MarketBeat
ABN Amro Investment Solutions Sells 8,219 Shares of Amgen Inc. $AMGN - MarketBeat
Aberdeen Group plc Sells 76,076 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Downgraded to "Hold" Rating by Freedom Capital - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Option Exercise |
169.70 |
3,139 |
532,691 |
8,864 |
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):